Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial | Trials | Full Text

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial | Trials | Full Text

Rivaroxaban compared to no treatment in ER-negative stage I–III early breast cancer patients (the TIP Trial): study protocol for a phase II preoperative window-of-opportunity study design randomised controlled trial

Breast cancer patients are at a four-fold increased risk of developing a venous thromboembolism (VTE), a major cause of death in this group. Conversely, coagulation factors promote tumour growth and metastasis...

Authors:John Castle, Emma Blower, Nigel J. Bundred, James R. Harvey, Jecko Thachil, Andrea Marshall, Karina Cox, Silvia Cicconi, Chris Holcombe, Carlos Palmieri and Cliona C. Kirwan

Citation:Trials 2020 21:749

Content type:Study protocol

 

Published on: 27 August 2020

• ViewFull Text
 
• ViewPDF